Register Today: Advancing Clinical Research of Gene Therapies in Brazil
FREE—December 2, 2020, 2-6 p.m. BRT

This event is in partnership between ASGCT and the Brazilian Association of Cellular and Gene Therapy. The goal of this program is for speakers with experience in clinical development to share their experiences and insights on factors to consider to successfully initiate clinical trials of in vivo and ex vivo gene therapies in Brazil. Stimulating such additional clinical research is an important step in expanding availability and access to these therapies for patients in need in the area.

Agenda

2 – 2:30 p.m. Brasilia Standard Time – Introduction

Kenneth Cornetta, M.D.
Indiana University
Chair, Global Outreach Committee, ASGCT

Sang W. Han, Ph.D.
Universidade Federal de São Paulo
Vice President, ABTCEL-GEN

https://www.asgct.org/brazil
2:30 – 2:50 p.m. – **Renato Cunha, M.D., Ph.D.**
Ribeirão Preto Medical School - São Paulo University
*Getting CAR T-cell therapy for leukemia into clinical trials in Brazil: Challenges and opportunities*

2:50 – 3:10 p.m. – **Richard C. Koya, M.D., Ph.D.**
Roswell Park Comprehensive Cancer Center
*Considerations for developing genetically modified T-cell therapy trials*

3:10 – 3:30 p.m. – Panel discussion

3:30 – 3:50 p.m. – Break

3:50 – 5:20 p.m. – Developing gene therapy clinical trials for monogenic diseases

3:50 – 4:10 p.m. – **Temis Maria Felix, Ph.D.**
Medical Genetics Service of Hospital de Clínicas de Porto Alegre
*Epidemiology of monogenic disorders in Brazil*

4:10 – 4:30 p.m. – **Margareth Castro Ozelo, M.D., Ph.D.**
WFH International Haemophilia Training Centre at the University of Campinas
*Getting gene therapy for hemophilia into clinical trials in Brazil: Challenges and opportunities*

4:30 – 4:50 p.m. – **Punam Malik, M.D.**
Cincinnati Children's Hospital Medical Center
*Considerations for early clinical trials on gene transfer*

4:50 – 5:20 p.m. – Panel discussion

5:20 – 5:50 p.m. – **Maritza McIntyre, Ph.D.**
StrideBio
*Regulatory considerations for early gene therapy trials*

5:50 – 6 p.m. Closing remarks